… the earliest sign of Parkinson’s disease (PD) identified to date. CSF has a simpler composition than blood or saliva. To detect these synuclein … seed amplification assay (synSAA), which is the same test that detect these aggregates in CSF. If this method …

… disease (PD) patients. This therapy can alleviate motor symptoms and improve quality of life, but it does … in pre-clinical models improved motor symptoms and showed neuronal protection. The Michael J. Fox Foundation … a surgeon implants a thin electrode into the brain, targeting motor circuits that are not functioning properly. …

… model of PD. Behavioural and biochemical techniques will be used to assess the efficacy of this approach as a treatment for PD. Relevance to Diagnosis/Treatment of Parkinson’s … a gene therapy approach to deliver the protein will overcome the issue of how to target specific brain regions and …

… the pre-clinical drug development research required to keep potential new therapies moving forward toward … have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression … preclinical PD research for biotech and pharmaceutical companies, thus expanding and catalyzing industry …

… Foundation Calls Computational Analysts to Develop Quantitative Models from Parkinson’s Progression … and testing; answers to these questions would help us target and treat this disease better and faster.” Submissions …

… it is unclear what causes the gradual worsening of the symptoms over the years. It is also unknown why in some cases … of other brain regions not affected by Parkinson's to compensate for basal ganglia dysfunction. Hypothesis: We … of Parkinson's disease: This study will demonstrate how compensatory mechanisms, such as neuroplasticity, …